developed the RED score for dysplasia, using hemoglobin levels, CD71 and CD36 expression (83), which, when combined with the hepcidin:ferritin ratio appears to predict response to erythropoietin (EPO) in lower-risk MDS (82). This evidence concerns the gene EPO and myelodysplastic syndrome.